Roche's lung cancer drug divarasib shows impressive data

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox.

We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a reminder that we’ll be recapping ESMO on Thursday at 10 a.m. Eastern. Register for the virtual event here, and thanks very much for reading.

Roche gets a lung cancer win

One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.

STAT+ Exclusive Story